Loading profile…
Pulling IRS BMF, Form 990 filings, peer benchmarks, programs, people, and grants.
Pulling IRS BMF, Form 990 filings, peer benchmarks, programs, people, and grants.
DBA: N/A
EIN 36-4712561 · Snapshot of IRS recognition, filing currency, financial health, and governance.
Develop position papers regarding the pathogenesis, diagnosis, treatment and prevention of Anal Neoplasia. Represent the consensus opinion of IANS regarding the above topics to other professional societies, public organizations, regulatory authorities and governmental bodies. Encourage the development of a robust research agenda on the pathogenesis, diagnosis, treatment and prevention of Anal Neoplasia. Develop educational materials and conduct training courses that encourage the entry of a broad spectrum of clinicians into the field of Anal Neoplasia, and that furthers the development and depth of skills of clinicians needed to optimally diagnose, treat and prevent Anal Neoplasia. Develop educational materials for patients with Anal Neoplasia.
Total Revenue
$508K
FY2025
Total Expenses
$518K
FY2025
Net Assets
$411K
Program Ratio
100.0%
expenses on programs
Employees
4
Volunteers
40
Board Members
12
Voting
12
Independent
8 answers compiled from IRS Form 990, BMF, Pub 78, and the Auto-Revocation List.